Verona Pharma Price Sales Ratio Over Time
| VRNA Stock | USD 39.68 0.87 2.24% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Verona Pharma Performance and Verona Pharma Correlation. Verona |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.07 | Return On Assets (0.28) | Return On Equity (0.78) |
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Price Sales Ratio Analysis
Compare Verona Pharma PLC and related stocks such as Ventyx Biosciences, Ideaya Biosciences, and Protagonist Therapeutics Price Sales Ratio Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VTYX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| IDYA | 17.7144 | 17.7144 | 17.7144 | 17.7144 | 17.7144 | 17.7144 | 17.7144 | 17.7144 | 17.7144 | 17.7144 | 17.7144 | 29.826 | 14.7857 | 87.5159 | 91.89 |
| PTGX | 18.3445 | 18.3445 | 18.3445 | 18.3445 | 18.3445 | 18.3445 | 18.3445 | 18.3445 | 4.867 | 790 | 24.2222 | 57.91 | 20.1291 | 21.6931 | 20.61 |
| SNDX | 332 | 332 | 332 | 332 | 332 | 332 | 85.9208 | 87.256 | 74.4253 | 176 | 606 | 8.1577 | 8.1577 | 7.34 | 6.97 |
| DAWN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| XFOR | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 1.8255 | 43.0317 | 43.0317 | 43.0317 | 43.0317 | 38.73 | 40.66 |
| INZY | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| ABOS | 476 | 476 | 476 | 476 | 476 | 476 | 476 | 476 | 476 | 476 | 562 | 562 | 562 | 506 | 415 |
| MREO | (101) | (101) | (101) | (101) | (101) | (101) | (101) | (101) | (1.8 K) | (1.8 K) | 2.3 K | 17.1116 | 248 | 152 | 101 |
| MLTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| APLS | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 17.153 | 59.9646 | 72.7527 | 17.9128 | 33.56 |
| AKRO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| MDGL | 152 | 29.0624 | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.6 K | 3.3 K | 3.4 K |
| VKTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Verona Pharma PLC and related stocks such as Ventyx Biosciences, Ideaya Biosciences, and Protagonist Therapeutics Price Sales Ratio description
My Equities
My Current Equities and Potential Positions
| Verona Pharma PLC | VRNA |
| Classification | Pharmaceutical Products |
| Location | United Kingdom |
| Exchange | NASDAQ Exchange |
USD 39.68
Check out Verona Pharma Performance and Verona Pharma Correlation. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Verona Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.